Know Cancer

or
forgot password

Early Chemotherapy Intensification With BEACOPP in High-Risk, Interim-PET Positive Advanced-Stage Hodgkin Lymphoma:a GITIL Retrospective Multicenter Clinical Study


N/A
16 Years
80 Years
Open (Enrolling)
Both
Hodgkin Lymphoma

Thank you

Trial Information

Early Chemotherapy Intensification With BEACOPP in High-Risk, Interim-PET Positive Advanced-Stage Hodgkin Lymphoma:a GITIL Retrospective Multicenter Clinical Study


Inclusion Criteria:



- Patients with advanced Hodgkin's lymphoma according to the World Health
Organization classification

- Age 16-80

- Not previously treated

- Stage IIB to IVB or stage IIA with adverse prognostic factors (more than 3 nodal
sites, ESR > 50 mm, bulky lesion)

- Written informed consent

Exclusion Criteria:

- Patients aged more than 80

- Concomitant or previously treated neoplastic disorder less than 5 years before the
diagnosis of Hodgkin's lymphoma

- Psychiatric disorders

- Uncontrolled infectious disease

- Impaired cardiac (EF < 50%) or renal (creatinine clearance < 60 ml/m)function

- Pregnancy and lactation

- Uncompensated diabetes mellitus and fasting glucose levels over 200 mg/dl

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

Progression Free Survival

Outcome Time Frame:

2 years

Safety Issue:

No

Principal Investigator

Andrea Gallamini, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Azienda Ospedaliera Santa Croce e Carle

Authority:

Italy: Ethics Committee

Study ID:

HD-PET-intens-retr

NCT ID:

NCT00877747

Start Date:

January 2006

Completion Date:

September 2009

Related Keywords:

  • Hodgkin Lymphoma
  • PET
  • Hodgkin Disease
  • Lymphoma

Name

Location